Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ and Holman RR (2002). "UKPDS 59:
hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes." Diabetes Care 25(5): 894-899.
Allende ML, Yamashita T and Proia RL (2003). "G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation." Blood 102(10): 3665-3667.
Allende ML, Dreier JL, Mandala S and Proia RL (2004). "Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration." J Biol Chem 279(15): 15396-15401.
Anliker B and Chun J (2004). "Lysophospholipid G protein-coupled receptors." J Biol Chem 279(20):
20555-20558.
Argraves KM, Gazzolo PJ, Groh EM, Wilkerson BA, Matsuura BS, Twal WO, Hammad SM and Argraves WS (2008). "High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function." J Biol Chem 283(36): 25074-25081.
Arning C, Widder B, von Reutern GM, Stiegler H and Görtler M (2010). "[Revision of DEGUM ultrasound criteria for grading internal carotid artery stenoses and transfer to NASCET measurement]."
Ultraschall Med 31(3): 251-257.
Bartholomew JR and Olin JW (2006). "Pathophysiology of peripheral arterial disease and risk factors for its development." Cleve Clin J Med 73 Suppl 4: S8-14.
Bekpinar S, Yenidunya G, Gurdol F, Unlucerci Y, Aycan-Ustyol E and Dinccag N (2015). "The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes." Clin Biochem 48(18): 1264-1267.
Bode C, Sensken SC, Peest U, Beutel G, Thol F, Levkau B, Li Z, Bittman R, Huang T, Tolle M, van der Giet M and Graler MH (2010). "Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate." J Cell Biochem 109(6): 1232-1243.
Bosiers M, Deloose K, Callaert J, Maene L, Beelen R, Keirse K, Verbist J, Peeters P, Schroë H, Lauwers G, Lansink W, Vanslembroeck K, D'archambeau O, Hendriks J, Lauwers P, Vermassen F, Randon C, Van Herzeele I, De Ryck F, De Letter J, Lanckneus M, Van Betsbrugge M, Thomas B, Deleersnijder R, Vandekerkhof J, Baeyens I, Berghmans T, Buttiens J, Van Den Brande P, Debing E, Rabbia C, Ruffino A, Tealdi D, Nano G, Stegher S, Gasparini D, Piccoli G, Coppi G, Silingardi R, Cataldi V, Paroni G, Palazzo V, Stella A, Gargiulo M, Muccini N, Nessi F, Ferrero
Literaturverzeichnis
79
E, Pratesi C, Fargion A, Chiesa R, Marone E, Bertoglio L, Cremonesi A, Dozza L, Galzerano G, De Donato G, Setacci C (2013). "BRAVISSIMO: 12-month results from a large scale prospective trial." J Cardiovasc Surg (Torino) 54(2): 235-253.
Brown TM and Bittner V (2008). "Biomarkers of atherosclerosis: clinical applications." Curr Cardiol Rep 10(6): 497-504.
Caligan TB, Peters K, Ou J, Wang E, Saba J and Merrill AH Jr. (2000). "A high-performance liquid chromatographic method to measure sphingosine 1-phosphate and related compounds from sphingosine kinase assays and other biological samples." Anal Biochem 281(1): 36-44.
Canpolat U, Turak O, Özcan F, Öksüz F, Mendi MA, Yayla Ç and Aydoğdu S (2017). "Impact of free thyroxine levels and other clinical factors on bare metal stent restenosis." Arch Endocrinol Metab 61(2): 130-136.
Cao P, De Rango P, Zannetti S, Giordano G, Ricci S and Celani MG (2001). "Eversion versus conventional carotid endarterectomy for preventing stroke." Cochrane Database Syst Rev(1):
CD001921.
Casscells W, Engler D and Willerson JT (1994). "Mechanisms of restenosis." Tex Heart Inst J 21(1): 68-77.
Chalfant CE and Spiegel S (2005). "Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling." J Cell Sci 118(Pt 20): 4605-4612.
Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnström J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB and Dahlbäck B (2011). "Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M." Proc Natl Acad Sci U S A 108(23):
9613-9618.
Clowes AW, Reidy MA and Clowes MM (1983). "Mechanisms of stenosis after arterial injury." Lab Invest 49(2): 208-215.
Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S and Goodman D (1985). "The prevalence of peripheral arterial disease in a defined population." Circulation 71(3): 510-515.
Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S and Spiegel S (1996). "Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate." Nature 381(6585):
800-803.
Literaturverzeichnis
80
Daum G, Grabski AD and Reidy MA (2009). "Sphingosine 1-phosphate: a regulator of arterial lesions."
Arterioscler Thromb Vasc Biol 29(10): 1439-1443.
de Vries SO and Hunink MG (1997). "Results of aortic bifurcation grafts for aortoiliac occlusive disease:
a meta-analysis." J Vasc Surg 26(4): 558-569.
de Weerd M, Greving JP, Hedblad B, Lorenz MW, Mathiesen EB, O'Leary DH, Rosvall M, Sitzer M, Buskens E and Bots ML (2010). "Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis." Stroke 41(6): 1294-1297.
DeBakey ME (1975). "Successful carotid endarterectomy for cerebrovascular insufficiency. Nineteen-year follow-up." JAMA 233(10): 1083-1085.
DeBakey ME, Lawrie GM and Glaeser DH (1985). "Patterns of atherosclerosis and their surgical significance." Ann Surg 201(2): 115-131.
Debus ES and Gross-Fengels W (2012). Allgemeine gefäßchirurgische Nahttechniken. In: Operative und Interventionelle Gefäßmedizin. Debus ES, Gross-Fengels W (Hrsg.). Berlin, Heidelberg, Springer. 1: 240-254.
Deutschman DH, Carstens JS, Klepper RL, Smith WS, Page MT, Young TR, Gleason LA, Nakajima N and Sabbadini RA (2003). "Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate." Am Heart J 146(1): 62-68.
Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R, Lange S, Pittrow D, von Stritzky B, Tepohl G and Trampisch HJ (2004). "High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study." Atherosclerosis 172(1): 95-105.
Dohmen A, Falk J, Lawall H, Luedemann C and Schmidt-Trucksäss A (30.11.2015). "Nachsorge." In:
S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. Deutsche Gesellschaft für Angiologie – Gesellschaft für Gefäßmedizin e.V. (DGA) (Hrsg.).
URL:http://www.awmf.org/uploads/tx_szleitlinien/065-003l_S3_PAVK_periphere_arterielle_Verschlusskrankheitfinal-2016-04.pdf [Stand: 14.02.2018].
Dos Santos JC (1976). "Leriche memorial lecture. From embolectomy to endarterectomy or the fall of a myth." J Cardiovasc Surg (Torino) 17(2): 113-128.
Dotter CT and Judkins MP (1964). "Transluminal Treatment of Arteriosclerotic Obstruction. Description of a New Technic and a Preliminary Report of Its Application." Circulation 30: 654-670.
Literaturverzeichnis
81
Duvall WL and Vorchheimer DA (2004). "Multi-bed vascular disease and atherothrombosis: scope of the problem." J Thromb Thrombolysis 17(1): 51-61.
Eastcott HH, Pickering GW and Rob CG (1954). "Reconstruction of internal carotid artery in a patient with intermittent attacks of hemiplegia." Lancet 267(6846): 994-996.
Eckstein HH (2004). Operative Therapie extrakranieller Karotisstenosen. Chirurg 75(1):93-110.
Eckstein HH, Ringleb P, Allenberg JR, Berger J, Fraedrich G, Hacke W, Hennerici M, Stingele R, Fiehler J, Zeumer H and Jansen O. (2008). "Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial." Lancet Neurol 7(10): 893-902.
Eckstein HH, Assadian A, Kühnl A and Berger H (2012). Supraaortale Gefäße. In: Operative und Interventionelle Gefäßmedizin. Debus ES, Gross-Fengels W (Hrsg.). Berlin, Heidelberg, Springer. 1: 383-421.
Espinola-Klein C und Trampisch HJ (30.11.2015). "Definition und Epidemiologie." In: S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. Deutsche Gesellschaft für Angiologie – Gesellschaft für Gefäßmedizin e.V. (DGA) (Hrsg.).
URL:http://www.awmf.org/uploads/tx_szleitlinien/065-003l_S3_PAVK_periphere_arterielle_Verschlusskrankheitfinal-2016-04.pdf [Stand: 14.02.2018].
European Carotid Trialists Collaborative Group (1998). "Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST)."
Lancet 351(9113): 1379-1387.
Frangos SG, Gahtan V and Sumpio B (1999). "Localization of atherosclerosis: role of hemodynamics."
Arch Surg 134(10): 1142-1149.
Fyrst H and Saba JD (2010). "An update on sphingosine-1-phosphate and other sphingolipid mediators."
Nat Chem Biol 6(7): 489-497.
Gil PR, Japtok L and Kleuser B (2010). "Sphingosine 1-phosphate mediates chemotaxis of human primary fibroblasts via the S1P-receptor subtypes S1P(1) and S1P(3) and Smad-signalling."
Cytoskeleton (Hoboken) 67(12): 773-783.
Gomes L, Fernando S, Fernando RH, Wickramasinghe N, Shyamali NL, Ogg GS and Malavige GN (2014). "Sphingosine 1-phosphate in acute dengue infection." PLoS One 9(11): e113394.
Literaturverzeichnis
82
Grabski AD, Shimizu T, Deou J, Mahoney WM, Reidy MA and Daum G (2009). "Sphingosine-1-phosphate receptor-2 regulates expression of smooth muscle alpha-actin after arterial injury."
Arterioscler Thromb Vasc Biol 29(10): 1644-1650.
Gräler MH, Bernhardt G and Lipp M (1998). "EDG6, a novel G-protein-coupled receptor related to receptors for bioactive lysophospholipids, is specifically expressed in lymphoid tissue."
Genomics 53(2): 164-169.
Grüntzig A and Hopff H (1974). "Perkutane Rekanalisation chronischer arterieller Verschlüsse mit einem neuen Dilatationskatheter." Dtsch med Wochenschr 99(49): 2502-2505.
Hänel P, Andréani P and Gräler MH (2007). "Erythrocytes store and release sphingosine 1-phosphate in blood." FASEB J 21(4): 1202-1209.
Hirsch AT, Treat-Jacobson D, Lando HA and Hatsukami DK (1997). "The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease." Vasc Med 2(3): 243-251.
Huppert H, Schulte KL and Tacke J (30.11.2015). "Interventionelle Therapie der pAVK." In: S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit.
Deutsche Gesellschaft für Angiologie – Gesellschaft für Gefäßmedizin e.V. (DGA) (Hrsg.).
URL:http://www.awmf.org/uploads/tx_szleitlinien/065-003l_S3_PAVK_periphere_arterielle_Verschlusskrankheitfinal-2016-04.pdf [Stand: 14.02.2018].
Im DS, Heise CE, Ancellin N, O'Dowd BF, Shei GJ, Heavens RP, Rigby MR, Hla T, Mandala S, McAllister G, George SR and Lynch KR. (2000). "Characterization of a novel sphingosine 1-phosphate receptor, Edg-8." J Biol Chem 275(19): 14281-14286.
Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, Kingsbury MA, Yang AH, Zhang G, Brown JH and Chun J (2002). "Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP(B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3."
J Biol Chem 277(28): 25152-25159.
Ito K, Anada Y, Tani M, Ikeda M, Sano T, Kihara A and Igarashi Y (2007). "Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes." Biochem Biophys Res Commun 357(1): 212-217.
Jongkind V, Akkersdijk GJ, Yeung KK and Wisselink W (2010). "A systematic review of endovascular treatment of extensive aortoiliac occlusive disease." J Vasc Surg 52(5): 1376-1383.
Literaturverzeichnis
83
Kang JL, Patel VI, Conrad MF, Lamuraglia GM, Chung TK and Cambria RP (2008). "Common femoral artery occlusive disease: contemporary results following surgical endarterectomy." J Vasc Surg 48(4): 872-877.
Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW and FTY720 D2201 Study Group (2006). "Oral fingolimod (FTY720) for relapsing multiple sclerosis." N Engl J Med 355(11): 1124-1140.
Karuna R, Park R, Othman A, Holleboom AG, Motazacker MM, Sutter I, Kuivenhoven JA, Rohrer L, Matile H, Hornemann T, Stoffel M, Rentsch KM and von Eckardstein A (2011). "Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism." Atherosclerosis 219(2): 855-863.
Keul P, Tölle M, Lucke S, von Wnuck Lipinski K, Heusch G, Schuchardt M, van der Giet M and Levkau B (2007). "The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice." Arterioscler Thromb Vasc Biol 27(3): 607-613.
Keul P, Lucke S, von Wnuck Lipinski K, Bode C, Gräler M, Heusch G and Levkau B (2011).
"Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis." Circ Res 108(3): 314-323.
Knapp M, Lisowska A, Knapp P and Baranowski M (2013). "Dose-dependent effect of aspirin on the level of sphingolipids in human blood." Adv Med Sci 58(2): 274-281.
Kono M, Mi Y, Liu Y, Sasaki T, Allende ML, Wu YP, Yamashita T and Proia RL (2004). "The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis." J Biol Chem 279(28): 29367-29373.
Kono M, Belyantseva IA, Skoura A, Frolenkov GI, Starost MF, Dreier JL, Lidington D, Bolz SS, Friedman TB, Hla T and Proia RL (2007). "Deafness and stria vascularis defects in S1P2 receptor-null mice." J Biol Chem 282(14): 10690-10696.
Kumakura H, Kanai H, Araki Y, Hojo Y, Iwasaki T and Ichikawa S (2015). "15-Year Patency and Life Expectancy After Primary Stenting Guided by Intravascular Ultrasound for Iliac Artery Lesions in Peripheral Arterial Disease." JACC Cardiovasc Interv 8(14): 1893-1901.
Lacombe M (2005). "[The history of intermittent claudication due to arterial disease]. [Article in French]
" Ann Chir 130(6-7): 440-444.
Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Cao AJ, Jaff MR and Resilient Investigators (2012). "Nitinol
Literaturverzeichnis
84
stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial." J Endovasc Ther 19(1): 1-9.
Lawall H, Huppert P and Rümenapf G (30.11.2015)a. "Therapie der pAVK. In:" S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. Deutsche Gesellschaft für Angiologie – Gesellschaft für Gefäßmedizin e.V. (DGA) (Hrsg.).
URL:http://www.awmf.org/uploads/tx_szleitlinien/065-003l_S3_PAVK_periphere_arterielle_Verschlusskrankheitfinal-2016-04.pdf [Stand: 14.02.2018].
Lawall H, Creutzig A and Dohmen A (30.11.2015)b. "Konservative Therapie der pAVK." In: S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit.
Deutsche Gesellschaft für Angiologie – Gesellschaft für Gefäßmedizin e.V. (DGA) (Hrsg.).
URL:http://www.awmf.org/uploads/tx_szleitlinien/065-003l_S3_PAVK_periphere_arterielle_Verschlusskrankheitfinal-2016-04.pdf [Stand: 14.02.2018].
Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, Spiegel S and Hla T (1998).
"Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1." Science 279(5356): 1552-1555.
Levkau B (2015). "HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applications." Front Pharmacol 6: 243.
Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, Rosenfeldt HM, Nava VE, Chae SS, Lee MJ, Liu CH, Hla T, Spiegel S and Proia RL (2000). "Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation." J Clin Invest 106(8): 951-961.
Lucke S and Levkau B (2010). "Endothelial functions of sphingosine-1-phosphate." Cell Physiol Biochem 26(1): 87-96.
Lundblad C, Axelberg H and Grände PO (2013). "Treatment with the sphingosine-1-phosphate analogue FTY 720 reduces loss of plasma volume during experimental sepsis in the rat." Acta Anaesthesiol Scand 57(6): 713-718.
Maceyka M and Spiegel S (2014). "Sphingolipid metabolites in inflammatory disease." Nature 510(7503): 58-67.
Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL and Cyster JG (2004). "Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1." Nature 427(6972): 355-360.
Literaturverzeichnis
85
McCabe DJ, Pereira AC, Clifton A, Bland JM, Brown MM and CAVATAS Investigators (2005).
"Restenosis after carotid angioplasty, stenting, or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS)." Stroke 36(2): 281-286.
McGirt MJ, Perler BA, Brooke BS, Woodworth GF, Coon A, Jain S, Buck D, Roseborough GS, Tamargo RJ, Heller J, Freischlag JA and Williams GM (2005). "3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy." J Vasc Surg 42(5): 829-836; discussion 836-827.
Moritz E, Wegner D, Groß S, Bahls M, Dörr M, Felix SB, Ittermann T, Oswald S, Nauck M, Friedrich N, Böger RH, Daum G, Schwedhelm E and Rauch BH (2017). "Reference intervals for serum sphingosine-1-phosphate in the population-based Study of Health in Pomerania." Clin Chim Acta 468: 25-31.
Murabito JM, D'Agostino RB, Silbershatz H and Wilson WF (1997). "Intermittent claudication. A risk profile from The Framingham Heart Study." Circulation 96(1): 44-49.
Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, Ui M and Okajima F (2000). "Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions." Biochem J 352 Pt 3: 809-815.
Nofer JR, van der Giet M, Tölle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Gödecke A, Ishii I, Kleuser B, Schäfers M, Fobker M, Zidek W, Assmann G, Chun J and Levkau B (2004).
"HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3." J Clin Invest 113(4): 569-581.
Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G and Biessen EA (2007). "FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice." Circulation 115(4): 501-508.
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG and TASC II Working Group.
(2007). "Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)."
J Vasc Surg 45 Suppl S: S5-67.
North American Symptomatic Carotid Endarterectomy Trial Collaborators, Barnett HJM, Taylor DW, Haynes RB, Sackett DL, Peerless SJ, Ferguson GG, Fox AJ, Rankin RN, Hachinski VC, Wiebers DO and Eliasziw M (1991). "Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis." N Engl J Med 325(7): 445-453.
Obinata H and Hla T (2012). "Sphingosine 1-phosphate in coagulation and inflammation." Semin Immunopathol 34(1): 73-91.
Literaturverzeichnis
86
Okajima F (2002). "Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator?" Biochim Biophys Acta 1582(1-3): 132-137.
Okamoto H, Takuwa N, Yokomizo T, Sugimoto N, Sakurada S, Shigematsu H and Takuwa Y (2000).
"Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3." Mol Cell Biol 20(24):
9247-9261.
Olivera A and Spiegel S (1993). "Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens." Nature 365(6446): 557-560.
Ono Y, Kurano M, Ohkawa R, Yokota H, Igarashi K, Aoki J, Tozuka M and Yatomi Y (2013).
"Sphingosine 1-phosphate release from platelets during clot formation: close correlation between platelet count and serum sphingosine 1-phosphate concentration." Lipids Health Dis 12: 20.
Paik JH, Chae S, Lee MJ, Thangada S and Hla T (2001). "Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3- and beta1-containing integrins." J Biol Chem 276(15): 11830-11837.
Pakala R, Willerson JT and Benedict CR (1997). "Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation." Circulation 96(7): 2280-2286.
Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG and Coughlin SR. (2007). "Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate." Science 316(5822): 295-298.
Prüfer N, Kleuser B and van der Giet M (2015). "The role of serum amyloid A and sphingosine-1-phosphate on high-density lipoprotein functionality." Biol Chem 396(6-7): 573-583.
Punsawad C and Viriyavejakul P (2017). "Reduction in serum sphingosine 1-phosphate concentration in malaria." PLoS One 12(6): e0180631.
Rerkasem K and Rothwell PM (2009). "Patch angioplasty versus primary closure for carotid endarterectomy." Cochrane Database Syst Rev(4): CD000160.
Ringleb P, Görtler M, Nabavi DG, Arning C, Sander D, Eckstein HH, Kühnl A, Berkefeld J, Diel R, Dörfler A, Kopp I, Langhoff R, Lawall H and Storck M (06.08.2012). "Symptome und Diagnostik von Carotisstenosen." In: S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der extracraniellen
Literaturverzeichnis
87
Carotisstenose. Deutsche Gesellschaft für Gefäßchirurgie und Gefäßmedizin - Gesellschaft für operative, endovaskuläre und präventive Gefäßmedizin e.V. (DGG) (Hrsg.).
URL:http://www.awmf.org/uploads/tx_szleitlinien/004-028l_S3_Extracranielle_Carotisstenose_2012_verlaengert.pdf [Stand:14.02.2018].
Ringleb P und Eckstein HH. (06.08.2012). "Therapieverfahren." In: S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der extracraniellen Carotisstenose. Deutsche Gesellschaft für Gefäßchirurgie und Gefäßmedizin - Gesellschaft für operative, endovaskuläre und präventive Gefäßmedizin e.V. (DGG) (Hrsg.).
URL:http://www.awmf.org/uploads/tx_szleitlinien/004-028l_S3_Extracranielle_Carotisstenose_2012_verlaengert.pdf [Stand: 14.02.2018].
Ross R (1999). "Atherosclerosis - an inflammatory disease." N Engl J Med 340(2): 115-126.
Rümenapf G (30.11.2015). "Chirurgische Therapie." In: S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. Deutsche Gesellschaft für Angiologie - Gesellschaft für Gefäßmedizin e.V. (DGA) (Hrsg.).
URL:http://www.awmf.org/uploads/tx_szleitlinien/065-003l_S3_PAVK_periphere_arterielle_Verschlusskrankheitfinal-2016-04.pdf [Stand 14.02.2018].
Sadideen H, Taylor PR and Padayachee TS (2006). "Restenosis after carotid endarterectomy." Int J Clin Pract 60(12): 1625-1630.
Sanchez T, Skoura A, Wu MT, Casserly B, Harrington EO and Hla T (2007). “Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN.” Arterioscler Thromb Vasc Biol 27(6):1312-1318.
Sattler K and Levkau B (2009). "Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection." Cardiovasc Res 82(2): 201-211.
Sattler KJ, Elbasan S, Keul P, Elter-Schulz M, Bode C, Graler MH, Brocker-Preuss M, Budde T, Erbel R, Heusch G and Levkau B (2010). "Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease." Basic Res Cardiol 105(6): 821-832.
Sattler K, Lehmann I, Graler M, Brocker-Preuss M, Erbel R, Heusch G and Levkau B (2014). "HDL-bound sphingosine 1-phosphate (S1P) predicts the severity of coronary artery atherosclerosis."
Cell Physiol Biochem 34(1): 172-184.
Seldinger SI (1953). "Catheter replacement of the needle in percutaneous arteriography; a new technique." Acta radiol 39(5): 368-376.
Literaturverzeichnis
88
Selvin E. and Erlinger TP (2004). "Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000."
Circulation 110(6): 738-743.
Shalhoub J, Owen DRJ, Gauthier T, Monaco C, Leen ELS and Davies AH (2010). "The use of contrast enhanced ultrasound in carotid arterial disease." Eur J Vasc Endovasc Surg 39(4): 381-387.
Shimizu T, Nakazawa T, Cho A, Dastvan F, Shilling D, Daum G and Reidy MA (2007). "Sphingosine 1-phosphate receptor 2 negatively regulates neointimal formation in mouse arteries." Circ Res 101(10): 995-1000.
Shimizu T, De Wispelaere A, Winkler M, D'Souza T, Caylor J, Chen L, Dastvan F, Deou J, Cho A, Larena-Avellaneda A, Reidy M and Daum G (2012). "Sphingosine-1-phosphate receptor 3 promotes neointimal hyperplasia in mouse iliac-femoral arteries." Arterioscler Thromb Vasc Biol 32(4): 955-961.
Soltau I, Mudersbach E, Geissen M, Schwedhelm E, Winkler MS, Geffken M, Peine S, Schoen G, Debus ES, Larena-Avellaneda A and Daum G (2016). "Serum-Sphingosine-1-Phosphate Concentrations Are Inversely Associated with Atherosclerotic Diseases in Humans." PLoS One 11(12).
Spence JD, Coates V, Li H, Tamayo A, Muñoz C, Hackam DG, DiCicco M, DesRoches J, Bogiatzi C, Klein J, Madrenas J and Hegele RA (2010). "Effects of intensive medical therapy on microemboli and cardiovascular risk in asymptomatic carotid stenosis." Arch Neurol 67(2): 180-186.
Staub D, Partovi S, Schinkel AF, Coll B, Uthoff H, Aschwanden M, Jaeger KA and Feinstein SB (2011).
"Correlation of Carotid Artery Atherosclerotic Lesion Echogenicity and Severity at Standard US with Intraplaque Neovascularization Detected at Contrast-enhanced US." Radiology 258(2):
618-626.
Storck M and Krankenberg H (2012). Verschlusserkrankungen. In: Operative und Interventionelle Gefäßmedizin. Debus ES, Gross-Fengels W (Hrsg.). Berlin, Heideberg, Springer. 1: 634-643.
Tacke J, Stiegler H and Huppert P (30.11.2015). "Diagnose der pAVK." In: S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit. Deutsche Gesellschaft für Angiologie - Gesellschaft für Gefäßmedizin e.V. (DGA) (Hrsg.).
URL:http://www.awmf.org/uploads/tx_szleitlinien/065-003l_S3_PAVK_periphere_arterielle_Verschlusskrankheitfinal-2016-04.pdf [Stand: 14.02.2018]
Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Catapano AL, Reiner Z, De Backer G, Graham I,
Literaturverzeichnis
89
Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Perrone Filardi P, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committees (2011). "ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)."
Atherosclerosis 217 Suppl 1: S1-44.
Theilmeier G, Schmidt C, Herrmann J, Keul P, Schäfers M, Herrgott I, Mersmann J, Larmann J, Hermann S, Stypmann J, Schober O, Hildebrand R, Schulz R, Heusch G, Haude M, von Wnuck Lipinski K, Herzog C, Schmitz M, Erbel R, Chun J and Levkau B (2006). "High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor." Circulation 114(13):
1403-1409.
Thudichum JLW (1884) "A treatise on the chemical constitution of the brain." Bailliere, Tindall, and Cox:149.
Ucar, FM (2016). "A potential marker of bare metal stent restenosis: monocyte count - to- HDL cholesterol ratio." BMC Cardiovasc Disord 16(1): 186.
Ulrych T, Böhm A, Polzin A, Daum G, Nüsing RM, Geisslinger G, Hohlfeld T, Schrör K and Rauch BH (2011). "Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation." J Thromb Haemost 9(4): 790-798.
Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, Parikh NS, Habrukowich C and Hla T (2008). "Vascular endothelium as a contributor of plasma sphingosine 1-phosphate."
Circ Res 102(6): 669-676.
Wamhoff BR, Lynch KR, Macdonald TL and Owens GK (2008). "Sphingosine-1-phosphate receptor subtypes differentially regulate smooth muscle cell phenotype." Arterioscler Thromb Vasc Biol 28(8): 1454-1461.
Wattanakit K, Folsom AR, Selvin E, Weatherley BD, Pankow JS, Brancati FL and Hirsch AT (2005).
"Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study." Atherosclerosis 180(2): 389-397.
Weintraub WS (2007). "The pathophysiology and burden of restenosis." Am J Cardiol 100(5A): 3K-9K.
Wilkerson BA, Grass GD, Wing SB, Argraves WS and Argraves KM (2012). "Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1." J Biol Chem 287(53): 44645-44653.
Literaturverzeichnis
90
Winkler MS, Nierhaus A, Holzmann M, Mudersbach E, Bauer A, Robbe L, Zahrte C, Geffken M, Peine S, Schwedhelm E, Daum G, Kluge S and Zoellner C (2015). "Decreased serum concentrations of sphingosine-1-phosphate in sepsis." Crit Care 19: 372.
Wozniak G and Baumgartner R (2012). Prinzipien der Amputation. In: Operative und Interventionelle Gefäßmedizin. Debus ES, Gross-Fengels W (Hrsg.). Berlin, Heidelberg, Springer. 1: 968-982.
Yatomi Y, Ruan F, Hakomori S and Igarashi Y (1995a). "Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets." Blood 86(1): 193-202.
Yatomi Y, Ruan F, Ohta J, Welch RJ, Hakomori S and Igarashi Y (1995)b. "Quantitative measurement of sphingosine 1-phosphate in biological samples by acylation with radioactive acetic anhydride." Anal Biochem 230(2): 315-320.
Yatomi Y, Igarashi Y, Yang L, Hisano N, Qi R, Asazuma N, Satoh K, Ozaki Y and Kume S (1997).
"Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum." J Biochem 121(5): 969-973.
Yatomi Y, Ozaki Y, Ohmori T and Igarashi Y (2001). "Sphingosine 1-phosphate: synthesis and release."
Prostaglandins Other Lipid Mediat 64(1-4): 107-122.
Yatomi, Y. (2008). "Plasma sphingosine 1-phosphate metabolism and analysis." Biochim Biophys Acta 1780(3): 606-611.
Zhang H, Desai NN, Olivera A, Seki T, Brooker G and Spiegel S (1991). "Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation." J Cell Biol 114(1): 155-167.
Danksagung
91